Led · Series A · May 2026

SuperMeat develops cultivated chicken and is pursuing commercialization through a licensing-led strategy with Switzerland identified as its first target launch market. Over the past 18 months the company reported a cultivated chicken cost milestone of US$11.79 per pound at scale and entered a partnership with Stämm focused on continuous bioprocessing. It has expanded collaborations with Ajinomoto Co., Inc. and Migros subsidiary Group Micarna to advance its commercialization efforts. The company is preparing a regulatory submission in Switzerland and conducting consumer validation studies ahead of launch. Financially, SuperMeat announced an initial US$6 million close of a targeted US$10 million Series A-4 round backed by Agronomics Limited, Milk & Honey Ventures and New Agrarian Company.

Led · Convertible Note · Dec 2025

Founded in 2018, San Diego-based BlueNalu produces premium seafood directly from fish cells, eliminating the need to harvest wild fish. Its first commercial product is cell-cultivated bluefin tuna toro, which the company aims to launch through premium food-service partners once regulatory approvals are secured. The firm collaborates closely with regulators, chefs, distributors and strategic partners worldwide to build a scalable, responsible cultivated-seafood supply chain. Proceeds from the latest financing will fund U.S. and international regulatory engagement, initial commercial-launch activities and manufacturing-process optimization. BlueNalu also plans to deepen strategic partnerships across the value chain to support disciplined commercialization. Agronomics’ investment lifts its fully diluted ownership to 12.96%, giving BlueNalu a committed long-term backer with deep cellular-agriculture expertise. Although revenue figures are not yet disclosed, management positions the company as a leader in the emerging cultivated-seafood category.

Led · Debt Financing · Oct 2024

Liberation Labs is an early-stage US biomanufacturing company developing a purpose-built precision fermentation platform called Bio3 and a launch facility in Richmond, Indiana. The company is building a 600,000 L launch plant scheduled to be operational in Q1 2025 and is studying a flexible-use, commercial-scale 4 million L plant. Liberation Labs has no current revenues; its monthly operating costs are reported at $0.4 million and total liabilities were $43.8 million as of June 30, 2024. Management says it has signed letters of intent with potential customers representing over 200% of the launch facility’s available capacity in initial years across food, fuel, materials and pharmaceutical markets. Prior financings include $33.5 million raised in equity-linked instruments and secured commitments for an additional $55 million, including $30 million in equipment financing and a $25 million loan from Ameris Bank. The company has also received a $1.39 million DoD award for a feasibility study that could lead to further government funding for expanding bioindustrial manufacturing capacity. Liberation Labs is developing Bio3, a purpose-built biomanufacturing platform aiming to be the industrial biotechnology industry's global fabrication partner. The platform is designed to address a critical bottleneck faced by fermentation companies by offering design, build and operation of biomanufacturing facilities. The company broke ground in June 2023 on its first facility in Richmond, Indiana, which when complete will have 600k litres of fermentation capacity and potential expansion of an additional 4 million litres. The project is approximately halfway through its build program and, subject to completion of a Qualified Financing, is expected to be commissioned in Q1 2025. Financially, Liberation Labs has raised US$33.5M in equity-linked instruments to date and has formal commitments for US$55M in non-dilutive funding, including US$30M equipment financing and a US$25M USDA-backed loan from Ameris Bank. Recent financing activity includes a US$12.5M round that featured a US$10M Secured Convertible Promissory Note from Agronomics to support continued construction ahead of the planned Series A. Liberation Labs is building a purpose-built commercial-scale precision fermentation facility in Richmond, Indiana, with 600,000 liters of capacity expected to be operational by the end of 2024. The plant will produce bio-based proteins and other building-block ingredients for consumer packaged goods companies and industrial manufacturers, and the site covers end-to-end processing from sugar feedstock to final product. The company says the facility is designed for higher throughput and lower all-in manufacturing costs compared with retrofitted pharma CMOS and can run a broader range of organisms, including methanol-fed Pichia. Construction milestones include footings installed in August, concrete poured in September, and long-lead equipment ordered and under construction. Liberation Labs has continued to build out its corporate staff and local team as it prepares for operation. Financially, the company has secured $20 million in seed funding (including Agronomics and CPT Capital), $30 million in equipment financing, and a new $25 million USDA-backed loan while it raises a Series A. Liberation Labs commercializes precision fermentation and develops purpose-built manufacturing facilities to enable large-scale production of bio-based consumer products. The company is advancing its first commercial-scale precision fermentation plant in Richmond, Indiana, which it describes as the first purpose-built commercial-scale precision fermentation facility in the United States. The Richmond facility is planned to have 600,000 liters of fermentation capacity and a fully dedicated downstream process. Liberation Labs has commenced detailed design engineering, placed orders for major engineered equipment (including 150,000-liter fermenters and DSP separation and drying units), and is building out engineering and operations teams. Groundbreaking was expected in June 2023 with initial plant startup targeted by the end of 2024. The company secured $30 million in equipment financing and completed a seed raise that together support equipment procurement and continued team investment. Liberation Labs develops a precision fermentation platform and a global network of purpose-built manufacturing facilities to produce alternative proteins at scale. The company is led by CEO Mark Warner and is focused on commercializing its platform through large-scale production sites. With the recent seed financing, Liberation Labs plans to build out a 600,000-liter production facility as part of its initial manufacturing footprint. Near-term priorities include finalizing site selection, completing Front End Loading level 3 (FEL-3) engineering, ordering long-lead equipment, and building the operations team. The company projects commissioning and commercial production of its first facility by the end of 2024. The raise funds these capital and operational milestones as it scales toward commercial operations.

Led · Series B · Sep 2024

Meatable develops cultivated pork and beef using pluripotent stem cells and its patented opti-ox™ technology to generate mature muscle and fat cells in days. The company positions its product as real meat with taste, texture, and nutritional profiles comparable to conventional meat. Meatable aims to scale production to meet rising global demand while reducing environmental impact and eliminating the need to harvest animals. Its opti-ox™ approach was recognized by TIME as one of the best inventions of 2024. The company is headquartered in the Netherlands and is pursuing market entry and strategic partnerships in Asia. Meatable has announced collaborations and potential co-development projects to accelerate commercialization in the region. Meatable is a Dutch cultivated meat company developing cultivated pork products and pursuing commercialisation. The company has been awarded a €7.6M Innovation Credit from the Netherlands Enterprise Agency to improve productivity and reduce costs. Meatable intends to work as a partner to the conventional meat industry to roll out cultivated meat at scale. It previously raised $35 million last year in a round led by Agronomics to accelerate the launch of its products. Meatable has joined the APAC Society for Cellular Agriculture and its cultivated pork products are pending regulatory approval from the Singapore Food Agency. The company held the first officially approved cultivated meat tasting in the EU for its cultivated pork sausages and says it reduced production time for those sausages to four days. In May Meatable appointed Jeff Tripician as CEO to lead expansion into the US. Meatable develops cultivated pork products by taking animal cells without harming the animal and replicating natural growth using its patented “opti‑ox” technology and pluripotent stem cells. The company reports it has reduced production time for fat and muscle from three weeks to eight days by using 500‑liter bioreactors and achieving cell densities of 80 million cells per milliliter. Meatable has grown to a team of about 100, started production in Singapore, and held its first external tastings after Dutch regulators allowed them. The company is still pre‑revenue and will use new funding to scale processes and focus on cost reduction. Meatable plans to commercialize sausages and pork dumplings in Singapore starting in 2024 and aims to establish a U.S. presence in roughly two years. Leadership includes co‑founder and CEO Krijn de Nood. Meatable is a Dutch cultivated meat company developing cell‑based pork, beef and other meat products using its proprietary opti‑ox™ platform. The technology replicates natural fat and muscle growth to produce meat with the texture, taste and nutritional profile of traditional meat without slaughtering animals. Meatable says its process, when fully developed, can produce meat in weeks rather than the years required to raise livestock, and that it requires less land and water and emits fewer greenhouse gases. The company finalized its first showcase product in 2020 and has completed a pork showcase; it is now focusing development on cultivated pork and beef and notes its platform is adaptable to multiple species. Meatable plans to use new capital to advance small‑scale production at the Biotech Campus Delft and to diversify its product portfolio. Financially, Meatable has closed a $47 million Series A and reports total funding to date of $60 million. Meatable is an Amsterdam-based cultured meat company developing pork (and beef) cell‑based whole cuts. It secured a further US$10 million in seed funding, bringing its total investment to US$13 million. The new funds come primarily from pre-existing investors and include participation from Taavet Hinrikus and Albert Wenger, with a portion provided by the European Commission through its Eurostars Programme. Meatable says new technology will enable cultivation at scale and plans to expand its scaling and cost-reduction teams. The company intends to accelerate development of its beef and pork cells and its process for forming whole cuts of meat. Founder Krijn de Nood said they expect to unveil their first prototype and be ready to launch in summer 2020.

Participated · Series A · Apr 2024

Onego Bio is a Helsinki-based precision fermentation food‑biotech company that produces Bioalbumen®, a real egg protein made entirely animal-free. Founded in 2022 as a spinoff from VTT by CEO Maija Itkonen, the company is working with major food companies on formulations for baked goods, confectionery, snacks, sauces, pasta, meat alternatives, and more. It currently conducts commercial operations in San Diego, producing Bioalbumen® with co-manufacturers while finalizing plans for its first own manufacturing unit. A single full-scale manufacturing unit is planned to have a two-million-liter fermentation capacity, equivalent to the protein produced by six million laying hens. Onego is prioritizing North American commercialization where regulatory pathways are faster, and it plans to submit a GRAS notice to the FDA this year with hopes of receiving a "no questions" letter in 2025. Financially, the company has raised €65M to date, including a €50.5M raise in April 2024 and the recent €14M in new funding. Onego Bio develops Bioalbumen®, an animal-free egg white protein produced with patented fungal precision‑fermentation technology that is bioidentical to ovalbumin and nutritionally complete (PDCAAS 1.0, >90 g protein/100 g). The company demonstrated industrial production potential of 120 g/L in 250,000 L fermentation vessels and currently collaborates with over 25 CPG companies across baked goods, confectionery, snacks, sauces, pasta, and meat alternatives. Founded in 2022 as a VTT spinoff, Onego positions its technology for competitive price points versus conventional egg protein and emphasizes superior functionality, flavor neutrality, and scalability. The funding will support North American go‑to‑market efforts, scaling to industrial production, expanding a US commercial team, partnering with co‑manufacturers, and finalising in‑house manufacturing plans. Onego is pursuing self‑affirmed GRAS status this year, with an FDA no‑objections letter expected in 2025, and plans to launch first in North America before expanding to Europe, South America, and Asia. The company has raised a total of $56 million to date. Onego Bio is a Finnish biotech spin-off from VTT developing an animal-free egg white using precision fermentation. The company employs a commercially proven Trichoderma technology to produce ovalbumin, the primary egg white protein. It plans to commercialize Bioalbumen™ first as a food ingredient for the food industry and later launch consumer-branded products for baking and cooking. Onego positions its method as safe, sustainable and cost-effective, with claimed efficiency and productivity advantages. The team says the product addresses environmental, food-security and animal-welfare concerns linked to conventional egg production. Financially, the company has recently raised funding to accelerate R&D and product development. Onego Bio is a Helsinki-based biotech spin-off from VTT Technical Research Centre of Finland developing animal-free proteins such as egg white using a commercially-proven trichoderma technology. Led by CEO Maija Itkonen, the company aims to produce egg white without chickens to address environmental problems associated with eggs. Its core product is animal-free bioalbumen powder positioned as a food ingredient for the bakery and confectionery industries and as a protein supplement for fitness products. The company plans to build pilot production in Finland in the coming years and to acquire necessary commercial approvals for its first product. Longer-term plans include entering the consumer market with its own branded products for baking and cooking. Onego raised seed funding to commercialize its technology and advance these plans.